This is a preview of subscription content, log in via an institution to check access.
References
Bird A. P. 1986 CpG-rich islands and the function of DNA methylation. Nature 321, 209–213.
Caldas C., Hahn S. A., da Costa L. T., Redston M. S., Schutte M., Seymour A. B. et al. 1995 Frequent somatic mutations and homozygous deletions of the p16 (NTS1) gene in pancreatic adenocarcinoma. Nature Genet. 8, 27–32.
Callens N., Baert J. L., Monte D., Sunesen M., Van Lint C. and Launoit Y. 2003 Transcriptional regulation of the murine brca2 gene by CREB/ATF transcription factors. Biochem. Biophys. Res. Comm. 312, 702–707.
Collins N., McManus R., Wooster R., Mangion J., Seal S., Lakhani S. R. et al. 1995 Consistent loss of the wild type allele in breast cancers from a family linked to the brca2 gene on chromosome 13q12-13. Oncogene 10, 1673–1675.
Collins N., Wooster R. and Stratton M. R. 1997 Absence of methylation of CpG dinucleotides within the promoter of the breast and ovarian cancers. Brit. J. Cancer 76, 1150–1156.
Dhillon V. S., Shahid M. and Hussain S. A. 2004 CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in granulosa cell tumors (GCTs) of ovarian origin. Mol. Cancer 3, 33 (http://www.molecular-cancer.com/content/3/1/33).
Fearon E. R. 1997 Human cancer syndromes: clues to the origin and nature of cancer. Science 278, 1043–1050
Gonzales-Zulueta M., Bender C. M., Yang A. S., Ngyen T., Beart R. W., Van Tornaut J. M. and Jones P. A. 1995 Methylation of the 5′ CpG island of the p16/CDKN2 tumour suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55, 4531–4535.
Gras E., Cotes J., Diez O., Alanso C., Matias-Guiu X., Baiget M. and Prat J. 2001 Loss of heterozygosity on chromosome 13q12-14, BRCA2 mutations and lack of BRCA2 promoter hypermethylation in sporadic epithelial ovarian tumors. Cancer 92, 787–795.
Herman J. G. and Baylin S. B. 2003 Gene silencing in cancer in association with promoter hypermethylation. New Engl. J. Med. 349, 2042–2054.
Herman J. G., Latif F., Weng Y., Lerman M. I., Zbar B., Lui S. et al. 1994 Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA 91, 9700–9704.
Herman J. G., Merlo A., Lapidus R. G., Issa J. P., Davidson N. E., Sidransky D. and Baylin S. B. 1995 Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55, 4525–4530.
Kang H. J., Kim S. J., Noh D. Y., Park I. A., Choe K. J., Yoo O. J. and Kang H. S. 2001 Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma. Lab. Invest. 81, 573–579.
Lehmann U., Länger F., Feist H., Glöckner S., Hasemeier B. and Kreipe H. 2002 Quantitative assessment of promoter hypermethylation during breast cancer development. Am. J. Pathol. 160, 605–612.
Li Y., Bollag G., Clark R., Stevens J., Conroy L., Fults D. et al. 1992 Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell 69, 275–281.
Ohtani Fujita N., Fujita T., Aoike A., Osifchin N. E., Robbins P. D. and Sakai T. 1993 CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-supressor gene. Oncogene 8, 1063–1067.
Pogribny I. P., Pogribna M., Christman J. K. and James S. J. 2000 Single-site methylation within the p53 promoter region reduces gene expression in a reporter gene construct: possible in vivo relevance during tumorigenesis. Cancer Res. 60, 588–594.
Shamoo Y. 2003 Structural insights into BRCA2 function. Curr. Opin. Struct. Biol. 13, 206–211.
Shuin T., Kondo K., Torigoe S., Kishida T., Kubota Y., Hosaka M. et al. 1994 Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal carcinomas. Cancer Res. 54, 2852–2855.
Takahashi H., Chiu H. C., Bandera C. A., Bekbaht K., Lui P. C., Couch F. J. et al. 1996 Mutations of the BRCA2 gene ovarian carcinomas. Cancer Res. 56, 2738–2741.
Tang A., Varley J. M., Chakraborty S., Murphree A. L. and Fung Y. K. 1988 Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 242, 263–266.
Tavtigian S. V., Simard J., Rommens J., Couch F. J., Shattuck-Eidens D., Neuhausen S. et al. 1996 The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature Genet. 12, 333–337.
Williams C., Weber I., Williamson R. and Hjelm M. 1988 Guthrie spots for DNA-based carrier testing in cystic fibrosis. Lancet 2, 693.
Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J. et al. 1995 Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789–792.
Yoshiura K., Kanai Y., Ochiai A., Shimoyama Y., Sugimura T. and Hirohashi S. 1995 Silencing of E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl. Acad. Sci. USA 92, 7416–7419.
Author information
Authors and Affiliations
Corresponding author
Additional information
This manuscript was accepted for publication on 2 December 2006, and its publication was delayed due to an unfortunate breakdown of communications between the author and the journal.
Rights and permissions
About this article
Cite this article
Cucer, N., Taheri, S., Ok, E. et al. Methylation status of CpG islands at sites −59 to +96 in exon 1 of the BRCA2 gene varies in mammary tissue among women with sporadic breast cancer. J Genet 87, 155–158 (2008). https://doi.org/10.1007/s12041-008-0023-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12041-008-0023-5